I expect to see an increase in Fusilev sales of 5-8% on a quarterly basis for some time. It´s the only drug approved to be used with FU. You never have peak sales for a drug that´s appoved for colorectal cancer for such a short time. With possible new indications for our 2 approved drugs and 2 NDA´s in 2012 the market will recognize Spectrum soon. The growth should be rewarded with a p/e expansion over time.

I find no Biotech stock that is so undervalued while having 2 drugs approved and 2 near NDA. The cash position and the share buy back add to my bullishness.

QCOR is a nice example what happens when the market realizes the full potential of a company. 1 drug, but 19 indications. Look at the chart. I wouldn´t be suprised to see a similar move of SPPI especially with new indications and a possible new approval.

best

Ein